About Eagle Pharmaceuticals
Eagle Pharmaceuticals is a publicly listed company based in Woodcliff Lake (United States) founded in 2007. It develops injectable products for use in critical care, orphan diseases, and oncology. Eagle Pharmaceuticals has raised $12.35 million across 3 funding rounds from investors including Swiss National Bank. Eagle Pharmaceuticals has completed 2 acquisitions, including Acacia Pharma and Arsia Therapeutics. Eagle Pharmaceuticals offers products and services including BARHEMSYS, BYFAVO, PEMFEXY, BELRAPZO, and RYANODEX. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Eagle Pharmaceuticals, Inc.
Company details
Eagle Pharmaceuticals is a specialty pharmaceutical company that develops injectable products. Pipeline include: Bendamustine RTD (NDA filed, FDA ODD granted), an intravenous version for chronic lymphocytic leukemia; RTU bivalirudin (NDA filed), an anticoagulant in patients; Ryanodex (Phase 2, FDA ODD granted) for Exertional heat stroke and Pemetrexed (pre-clinical) for non-small cell lung cancer. The company went public in 2014.
- Headquarters Woodcliff Lake, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website eagleus.com
- Social LinkedIn Facebook
- Legal Name Eagle Pharmaceuticals Inc
- Annual Revenue$316.61 M (USD)84.56as on Dec 31, 2022
- Net Profit$35.64 M (USD)0as on Dec 31, 2022
- EBITDA$106.83 M (USD)1310.26as on Dec 31, 2022
- Total Equity Funding$12.35M (USD)
in 3 rounds
- Latest Funding Round$2.74M (USD), Post-IPO
Nov 2016
- Investors
- Investments & AcquisitionsAcacia Pharma
& 1 more
Products & Services of Eagle Pharmaceuticals
Eagle Pharmaceuticals offers a comprehensive portfolio of products and services, including BARHEMSYS, BYFAVO, PEMFEXY, BELRAPZO, and RYANODEX.
Treats post-operative nausea and vomiting in patients
Used for procedural sedation in medical settings
Provides chemotherapy treatment for cancer patients
Administers bendamustine for lymphoma therapy
Manages malignant hyperthermia in emergencies
Offers bendamustine treatment for blood cancers
Funding Insights of Eagle Pharmaceuticals
Eagle Pharmaceuticals has successfully raised a total of $12.35M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.74 million completed in November 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.35M
- Total Rounds 3
- Last Round Post-IPO — $2.74M
- First Round $12.35M
(Feb 2011)
- Investors Count 1
All 3 funding rounds of Eagle Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2016 | $2.74M | Post-IPO | – | – | – |
| Oct 2016 | $586,000 | Post-IPO | – | – | |
| Feb 2011 | $12.35M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in Eagle Pharmaceuticals
Eagle Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Swiss National Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Central banking functions are performed in Switzerland. | 1907 | snb.ch | Zurich, Switzerland |
Investor details for Eagle Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eagle Pharmaceuticals
36 people are tracked at Eagle Pharmaceuticals (26 in leadership, 10 in team).
| Name | Role | Group |
|---|---|---|
Scott Tarriff | Founder & CEO | Leadership |
Jayant Goundalkar | VP India Operations | Leadership |
Mark Bufkin | Vice President | Leadership |
John Archie | National Account Director, Oncology GPO | Leadership |
Jim Blissenbach | National Account Director | Leadership |
Shaun O'Connor | Director, Supply Chain | Leadership |
Ted M. | Sr. Director Quality Operations | Leadership |
Kimberly Finn | Director Of Trade/distribution/contracting-acute Care & Oncology | Leadership |
Ahmed Elgohail | Senior Director Of Oncology Contracting | Leadership |
Mhrm Tracy Straley | Senior Vice President, Human Resources At Eagle Pharmaceuticals, Inc. | Leadership |
David S. Bricker | Senior Vice President, Head Global Manufacturing And Supply | Leadership |
Marc Stern | Senior Director Of Regulatory Processes, Operations And Publishing | Leadership |
Valentin Razvan Curt | Interim Chief Medical Officer | Leadership |
Steve Lucas | Senior Director, Quality Operations | Leadership |
Tess Cordera | Associate Director Human Resources | Leadership |
Alvin Mok | Director Of Commercial Operations & Field Force Effectiveness (oncology) | Leadership |
Lynn Bichajian | Senior Medical Director, Clinical Drug Development | Leadership |
Paula Karabelas Pharmd, Hcc | Director, Investigative Compliance | Leadership |
Debra Hussain | Head Of Commercial For Acute Care/hospital | Leadership |
Alan Eagle | National Sales Director | Leadership |
16 more people are available in the full profile.
Complete people profiles for Eagle Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Eagle Pharmaceuticals
Eagle Pharmaceuticals is a publicly listed company on the OTC with ticker symbol EGRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Mar 2014
- Listed onFRA: 1E6
- Listed entityEAGLE PHARMACEUTICALS INC
- Exchange sectorHealth technology
- ISINUS2697961082
- Share price$0.89 (-8.76% on the day) · 2026-10-13
- Market capitalisation$11.5M
- Volume (last session)3,300
Financials of Eagle Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $316.6M | $35.6M | $106.8M |
| 2021 | $171.6M | -$8.6M | $7.6M |
| 2020 | $187.8M | $12.0M | $37.7M |
Detailed financial statements for Eagle Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eagle Pharmaceuticals
Eagle Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Acacia Pharma and Arsia Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of therapeutic solutions for treating cancer | acaciapharma.com | Cambridge, United Kingdom | 2006 | Mar 2022 | •••• | |
High-concentration biologics are formulated for low-viscosity subcutaneous injection. | arsiarx.com | Waltham, United States | 2013 | Nov 2016 | $30M |
Complete acquisition details for Eagle Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Eagle Pharmaceuticals
6 dated milestones of Eagle Pharmaceuticals across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Eagle Pharmaceuticals is founded.
- Funding First funding round of $12.3M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Arsia Therapeutics.
- Funding Latest funding round, Post-IPO, of $2.7M.
- Acquisition Acquires Acacia Pharma.
Web traffic of Eagle Pharmaceuticals
The website of Eagle Pharmaceuticals (eagleus.com) receives about 5K visits a month and ranks #3,954,012 among all websites worldwide, #4,991 in Biotechnology and Pharmaceuticals.
- Monthly visits5K
▲ 7.5% vs previous month
- Unique visitors1.9K
per month
- Global rank#3,954,012
among all websites
- Category rank#4,991
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.7
- Average visit32 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Eagle Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
mmm-online.com | mmm-online.com | 100% | – | #392,799 | – |
anesthesiologynews.com | anesthesiologynews.com | 65% | – | #921,057 | – |
| mhaus.org | 63% | 12.8K | #1,917,051 | View details | |
galdermausa.com | galdermausa.com | 61% | – | #8,329,898 | – |
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Eagle Pharmaceuticals (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eagle Pharmaceuticals
Complete news archive for Eagle Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eagle Pharmaceuticals
Eagle Pharmaceuticals was founded in 2007 and raised its 1st funding round 4 years after it was founded.
Eagle Pharmaceuticals is headquartered in Woodcliff Lake, United States. It is registered at Woodcliff Lake, New Jersey, United States.
Eagle Pharmaceuticals is a funded company, having raised a total of $12.35M across 3 funding rounds to date. The company's 1st funding round was a Series B of $12.35M, raised on Feb 2011.
Annual revenue of Eagle Pharmaceuticals is $316.61M as on Dec 31, 2022.
Eagle Pharmaceuticals is a specialty pharmaceutical company that develops injectable products. Pipeline include: Bendamustine RTD (NDA filed, FDA ODD granted), an intravenous version for chronic lymphocytic leukemia; RTU bivalirudin (NDA filed), an anticoagulant in patients; Ryanodex (Phase 2, FDA ODD granted) for Exertional heat stroke and Pemetrexed (pre-clinical) for non-small cell lung cancer. The company went public in 2014.
Eagle Pharmaceuticals offers BARHEMSYS, BYFAVO, PEMFEXY, BELRAPZO, and 2 more products and services.
Yes, Eagle Pharmaceuticals is publicly traded on OTC under the ticker symbol EGRX.
Eagle Pharmaceuticals has made 2 acquisitions, including Acacia Pharma, and Arsia Therapeutics.
Eagle Pharmaceuticals has 1 investor. Key investors include Swiss National Bank.
Eagle Pharmaceuticals operates through Eagle Pharmaceuticals, Inc..